173 related articles for article (PubMed ID: 16702958)
1. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
[TBL] [Abstract][Full Text] [Related]
2. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
3. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Cui Y; Guadagno TM
Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
5. Regulation and role of Raf-1/B-Raf heterodimerization.
Rushworth LK; Hindley AD; O'Neill E; Kolch W
Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
[TBL] [Abstract][Full Text] [Related]
6. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets.
Moodie SA; Paris M; Villafranca E; Kirshmeier P; Willumsen BM; Wolfman A
Oncogene; 1995 Aug; 11(3):447-54. PubMed ID: 7630628
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
[TBL] [Abstract][Full Text] [Related]
8. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
Emuss V; Garnett M; Mason C; Marais R
Cancer Res; 2005 Nov; 65(21):9719-26. PubMed ID: 16266992
[TBL] [Abstract][Full Text] [Related]
9. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
11. TC21 and Ras share indistinguishable transforming and differentiating activities.
Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
13. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Garnett MJ; Rana S; Paterson H; Barford D; Marais R
Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
Eisenhardt AE; Olbrich H; Röring M; Janzarik W; Anh TN; Cin H; Remke M; Witt H; Korshunov A; Pfister SM; Omran H; Brummer T
Int J Cancer; 2011 Nov; 129(9):2297-303. PubMed ID: 21190184
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells.
Zhang L; Shi R; He C; Cheng C; Song B; Cui H; Zhang Y; Zhao Z; Bi Y; Yang X; Miao X; Guo J; Chen X; Wang J; Li Y; Cheng X; Liu J; Cui Y
Cancer Lett; 2013 Aug; 337(1):125-32. PubMed ID: 23726842
[TBL] [Abstract][Full Text] [Related]
16. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.
Ramírez de Molina A; Penalva V; Lucas L; Lacal JC
Oncogene; 2002 Jan; 21(6):937-46. PubMed ID: 11840339
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of inactive B-RAF(WT) and B-RAF(V600E) ligand inhibition, selectivity and conformational stability: an in silico study.
Fratev F; Jónsdóttir SO; Mihaylova E; Pajeva I
Mol Pharm; 2009; 6(1):144-57. PubMed ID: 19248232
[TBL] [Abstract][Full Text] [Related]
18. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.
Leevers SJ; Paterson HF; Marshall CJ
Nature; 1994 Jun; 369(6479):411-4. PubMed ID: 8196769
[TBL] [Abstract][Full Text] [Related]
19. The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study.
Fratev F; Jónsdóttir SO
J Mol Graph Model; 2010 Apr; 28(7):598-603. PubMed ID: 20093060
[TBL] [Abstract][Full Text] [Related]
20. Mutations that abolish the ability of Ha-Ras to associate with Raf-1.
Shirouzu M; Koide H; Fujita-Yoshigaki J; Oshio H; Toyama Y; Yamasaki K; Fuhrman SA; Villafranca E; Kaziro Y; Yokoyama S
Oncogene; 1994 Aug; 9(8):2153-7. PubMed ID: 8036000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
